SCHEMBL8078

SCHEMBL8078

CCOc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 20/20 1.00
DRD4 P21917 8/20 0.85
DRD3 P35462 8/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10573201 0.97 DRD2 (0.95) DRD2DRD4DRD3
SCHEMBL250675 0.97 DRD2 (1.00) DRD2DRD4DRD3
SCHEMBL252295 0.92 DRD2 (1.00) DRD2DRD4DRD3
SCHEMBL14974690 0.91 DRD2 (1.00) DRD2DRD4DRD3
SCHEMBL3157625 0.90 DRD2 (0.81) DRD2DRD4DRD3
SCHEMBL3163009 0.89 DRD2 (0.80) DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL3153054 0.89 DRD2 (0.80) DRD2DRD4DRD3
SCHEMBL10570451 0.89 DRD2 (1.00) DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL3154859 0.89 DRD2 (0.79) DRD2DRD4DRD3
SCHEMBL251472 0.89 DRD2 (1.00) DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0367141-B1 Carbostyril derivatives OTSUKA PHARMA CO LTD (JP) 1996-01-10 EP claimed
US-5006528-A Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-04-09 US claimed
EP-0367141-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-05-09 EP claimed
JP-10045718-A None JP disclosed
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 US disclosed
US-8475804-B2 Compositions and methods for treatment of filovirus-mediated diseases U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2013-07-02 US disclosed
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES ZALICUS INC. 2011-02-03 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
JP-H1045718-A CARBOSTYRIL DERIVATIVE OTSUKA PHARMACEUT CO LTD 1998-02-17 JP disclosed
EP-0367141-B1 Carbostyril derivatives OTSUKA PHARMA CO LTD (JP) 1996-01-10 EP disclosed
US-5006528-A Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-04-09 US disclosed
EP-0367141-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR6, GAP43, HTR5A DRD2 242/4885DRD4 301/4885DRD3 432/4885
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS DRD2 4871/4885DRD4 4834/4885DRD3 4854/4885
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS DRD2 4871/4885DRD4 4834/4885DRD3 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.